NCT06292650 - Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2024

Primary Completion Date

December 25, 2027

Study Completion Date

December 25, 2028

Conditions

Retinitis Pigmentosa

Interventions

DRUG

ZM-02-L

rAAV-PsCatCh2.0 intravitreal injection of low dose

DRUG

ZM-02-H

rAAV-PsCatCh2.0 intravitreal injection of high dose

PROCEDURE

ZM-02-S

sham intravitreal injection of ZM-02 (not actual injection)

Trial Locations (1)

RECRUITING

Beijing Tongren Hospital of Capital Medical University, Beijing